Royalty Pharma
RPRX
RPRX
212 hedge funds and large institutions have $10.8B invested in Royalty Pharma in 2021 Q1 according to their latest regulatory filings, with 48 funds opening new positions, 85 increasing their positions, 56 reducing their positions, and 34 closing their positions.
Holders
212
Holders Change
+14
Holders Change %
+7.07%
% of All Funds
3.73%
Holding in Top 10
11
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+10%
% of All Funds
0.19%
New
48
Increased
85
Reduced
56
Closed
34
Calls
$46.5M
Puts
$45.7M
Net Calls
+$871K
Net Calls Change
+$22.2M
Top Buyers
| 1 |
1
Morgan Stanley
New York
|
$2.1B |
| 2 |
2
Vanguard Group
Malvern,
Pennsylvania
|
$982M |
| 3 |
3
BlackRock
New York
|
$596M |
| 4 |
4
Fidelity Investments
Boston,
Massachusetts
|
$1.22B |
| 5 |
5
State Street
Boston,
Massachusetts
|
$204M |
